Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $0.71 which represents a decrease of $-0.09 or -11.25% from the prior close of $0.8. The stock opened at $0.79 and touched a ...
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer ...
Lexicon completes patient enrollment in phase 2B PROGRESS study of LX9211 in diabetic peripheral neuropathic pain: The Woodlands, Texas Thursday, November 28, 2024, 12:00 Hrs [IST ...
Lexicon Pharmaceuticals has completed the enrolment of subjects for the multicentre, Phase IIb PROGRESS trial of the new ...
On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...
Derm-Biome Pharmaceuticals added Dr. Jerry Tan to its scientific advisory board. Lexicon Pharmaceuticals added former Eisai ...
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price ...
Lexicon Pharmaceuticals is shifting focus to its late-stage pipeline following the FDA's rejection of Zynquista for type 1 ...
Needham & Company LLC reaffirmed their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research note published on Friday,Benzinga reports. LXRX has been the subject ...
Detailed price information for Lexicon Pharmaceutcl (LXRX-Q) from The Globe and Mail including charting and trades.
For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.
The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application ...